Personalis, Inc. cotiza a 15.85 USD y tiene una capitalización bursátil de $1.7B. En los últimos 12 meses ha facturado $70M con un margen de flujo de caja libre del -114.1%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.30 | $-0.29 | $-0.26 |
| Estimado | $-0.25 | $-0.28 | $-0.28 | $-0.28 |
| Sorpresa | — | -7.1% | -3.6% | +7.1% |
| Métrica | PSNL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 22.6% | 57.0% | -34.4% |
| Operating Margin | -126.4% | -38.6% | -87.8% |
| Net Margin | -116.7% | -33.6% | -83.1% |
| FCF Margin | -114.1% | -13.9% | -100.2% |
| ROE | -31.1% | -40.4% | +9.3% |
| ROA | -24.3% | -32.0% | +7.7% |
| Current Ratio | 6.76 | 2.84 | +3.92 |
| Debt / Equity | — | 0.28 | — |